Health
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer – Medical Xpress
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung…
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas MD Anderson Cancer Center published the study results today in Nature Medicine.
The NEOSTAR…
-
Noosa News20 hours agoQueensland weather forecast sees sunny weather for last week of winter
-
General23 hours agoFirst home buyers score early access to deposit scheme
-
General14 hours agoMigrants raise concerns over Australia’s English tests for visa applicants
-
Noosa News21 hours agoForum responds to urgent homelessness issues in Nambour